Reply to the Letter to the Editor regarding ‘PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?’ by T. Nishimura and H. Fujimoto... von Felip, E., Cho, B.C., Nguyen, D., Curtin, J.C., Sethi, S., Bauml, J.M., Lee, S.-H.

Volltext

1202P A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC von Parmar, C., Juan Ramon, A., Raciti, P., Standish, K., Chowdhury, S., Shah, S., Cruz-Guilloty, F., Curtin, J.C., Baig, M., Schnepp, R.W., Lyu, X., Albertyn, Z., Moy, C., Greshock, J., Demirdjian, L.

Volltext

LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early anal... von Besse, B., Lee, S-H., Lu, S., Stroyakovskiy, D., Yazici, O., Rodriguez Cid, J.R., Hayashi, H., Nguyen, D., Yang, J.C-H., Gottfried, M., Gelatti, A.C., Owen, S., Ou, S-H.I., Ennis, M., Sethi, S., Bauml, J.M., Zhang, J., Curtin, J.C., Cho, B.C.

Volltext

513MO Amivantamab plus FOLFOX or FOLFIRI in metastatic colorectal cancer: Results from OrigAMI-1, an open-label, phase Ib/II study von Pietrantonio, F., Ho, G.F., Su, Y-L., Chen, E.X., Yuan, Y., Voon, P-J., Liang, X., Jonker, D., Muñoz, F. Longo, Hecht, J.R., Chandana, S., Arnold, D., Bhattacharya, R., Curtin, J.C., Maul, S., Iwasawa, R., Chowdhury, S., Schnepp, R.W., Baig, M., Hong, Y.S.

Volltext

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOS... von Felip, E., Cho, B.C., Gutiérrez, V., Alip, A., Besse, B., Lu, S., Spira, A.I., Girard, N., Califano, R., Gadgeel, S.M., Yang, J.C.-H., Yamamoto, S., Azuma, K., Kim, Y.J., Lee, K.-H., Danchaivijitr, P., Ferreira, C.G., Cheng, Y., Sendur, M.A.N., Chang, G.-C., Wang, C.-C., Prabhash, K., Shinno, Y., Stroyakovskiy, D., Paz-Ares, L., Rodriguez-Cid, J.R., Martin, C., Campelo, M.R.G., Hayashi, H., Nguyen, D., Tomasini, P., Gottfried, M., Dooms, C., Passaro, A., Schuler, M., Gelatti, A.C.Z., Owen, S., Perdrizet, K., Ou, S.-H.I., Curtin, J.C., Zhang, J., Gormley, M., Sun, T., Panchal, A., Ennis, M., Fennema, E., Daksh, M., Sethi, S., Bauml, J.M., Lee, S.-H.

Volltext

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOS... von Felip, E, Cho, B.C, Gutierrez, V, Alip, A, Besse, B, Lu, S, Spira, A.I, Girard, N, Califano, R, Gadgeel, S.M, Yang, J.C.-H, Yamamoto, S, Azuma, K, Kim, Y.J, Lee, K.-H, Danchaivijitr, P, Ferreira, C.G, Cheng, Y, Sendur, M.A.N, Chang, G.-C, Wang, C.-C, Prabhash, K, Shinno, Y, Stroyakovskiy, D, Paz-Ares, L, Rodriguez-Cid, J.R, Martin, C, Campelo, M.R.G, Hayashi, H, Nguyen, D, Tomasini, P, Gottfried, M, Dooms, C, Passaro, A, Schuler, M, Gelatti, A.C.Z, Owen, S, Perdrizet, K, Ou, S.-H.I, Curtin, J.C, Zhang, J, Gormley, M, Sun, T, Panchal, A, Ennis, M, Fennema, E, Bauml, J.M, Daksh, M, Sethi, S, Lee, S.-H

Volltext

OA02.05 Lazertinib vs Osimertinib in 1L EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis from MARIPOSA von Lee, S.-H., Cho, B.C., Hayashi, H., Felip, E., Spira, A.I., Girard, N., Kim, Y.J., Ostapenko, Y., Danchaivijitr, P., Liu, B., Alip, A., Korbenfeld, E., Mourão Dias, J., Lee, K.H., Xiong, H., How, S.H., Cheng, Y., Chang, G.-C., Yang, J.C.-H., Besse, B., Thomas, M., Curtin, J.C., Zhang, J., Xie, J., Sun, T., Martinez, M., Sethi, S., Knoblauch, R.E., Fennema, E., Daksh, M., Ennis, M., Bauml, J.M., Lu, S.

Volltext

1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab von Park, K., Sabari, J.K., Haura, E.B., Shu, C.A., Spira, A., Salgia, R., Reckamp, K.L., Sanborn, R.E., Govindan, R., Bauml, J.M., Curtin, J.C., Xie, J., Roshak, A., Lorenzini, P., Millington, D., Thayu, M., Knoblauch, R.E., Cho, B.C.

Volltext

OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study von Leighl, N., Cho, B.C., Hiret, S., Han, J.-Y., Lee, K.H., Llacer Perez, C., Krebs, M.G., De Braud, F., Haura, E., Sanborn, R.E., Yang, J.C.-H., Shu, C.A., Goto, K., Nishio, M., Zhao, J., Wang, Z., Tomasini, P., Felip, E., Goldman, J.W., Ou, S.-H.I., Boyer, M., Gao, G., Qu, S., Curtin, J.C., Lyu, X., Roshak, A., Schnepp, R.W., Kim, P., Mertz, J., Thayu, M., Shreeve, S.M., Knoblauch, R.E., Spira, A.I.

Volltext

P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) von Cho, B.C., Lee, S.-H., Han, J.-Y., Cho, E.K., Lee, J.-S., Lee, K.H., Curtin, J.C., Gao, G., Xie, J., Schnepp, R.W., Bauml, J.M., Knoblauch, R.E., Thayu, M., Kim, D.-W.

Volltext

P76.74 PAPILLON: Randomized Phase 3 Study of Amivantamab Plus Chemotherapy vs Chemotherapy Alone in EGFR Exon20ins NSCLC von Agrawal, T., Artis, E., Xie, J., Bhattacharya, A., Haddish-Berhane, N., Gopen, T., Curtin, J.C., Karkera, J., Roshak, A., Knoblauch, R.E., Patel, K.

Volltext

P76.73 MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab + Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC von Shreeve, S.M., Martinez, M., Verheijen, R.B., Xie, J., Sun, T., Haddish-Berhane, N., Curtin, J.C., Karkera, J., Pang, D., Roshak, A., Knoblauch, R.E., Patel, K.

Volltext

MA12.06 PAPILLON: TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC von Goldman, J.W., Cho, B.C., Cheng, S., Zhou, C., Liu, B., Yao, Y., Alip, A., Kim, Y.J., Parra, H.J. Soto, Kawamura, T., Hataji, O., Hayashi, H., Zurawski, B., Batra, U., Santos, V., Teixeira, E., Dooms, C., Alatorre-Alexander, J., Girard, N., Spira, A.I., Kim, C., Sabari, J.K., Popat, S., Park, K., Sanborn, R.E., Curtin, J.C., Zhang, J., Luo, X., Lyu, X., Bhattacharya, A., Lorenzini, P., Wortman-Vayn, H., Baig, M., Agrawal, T., Knoblauch, R.E., Mansfield, A.S.

Volltext

P1.01-94 JNJ-61186372, an EGFR-cMet Bispecific Antibody, in EGFR Exon 20 Insertion-Driven Advanced NSCLC von Yun, J., Kang, H.N., Lee, S., Park, C., Jeong, S., Hong, M.H., Kim, H.R., Thayu, M., Curtin, J.C., Knoblauch, R.E., Lorenzi, M.V., Roshak, A., Cho, B.C.

Volltext

Chronic autoreceptor blockade and neuroleptic-induced dopamine receptor hypersensitivity von Gordon, John H., Kirk Clopton, J., Curtin, J.C., Koller, William C.

Volltext

How readable are your nutrition education materials [test formulas]. [Conference paper] von Begley, A.M, Scott, J.A, Richards, J.C. (Curtin Univ. of Technology, Perth (Australia))

Volltext

A physiologically relevant 3D collagen-based scaffold–neuroblastoma cell system exhibits chemosensitivity similar to orthotopic xenograft models von Curtin, C., Nolan, J.C., Conlon, R., Deneweth, L., Gallagher, C., Tan, Y.J., Cavanagh, B.L., Asraf, A.Z., Harvey, H., Miller-Delaney, S., Shohet, J., Bray, I., O'Brien, F.J., Stallings, R.L., Piskareva, O.

Volltext

Preclinical models for neuroblastoma: Advances and challenges von Nolan, J.C., Frawley, T., Tighe, J., Soh, H., Curtin, C., Piskareva, O.

Volltext

Searching for long-lived particles beyond the Standard Model at the Large Hadron Collider von Borsato, Martino, Cottin, Giovanna, Curtin, David, Desai, Nishita, Evans, Jared A, Knapen, Simon, Kraml, Sabine, Lessa, Andre, Russell, Heather, Shelton, Jessie, Shuve, Brian, Adersberger, Michael, Alpigiani, Cristiano, Bainbridge, Robert John, Beauchesne, Hugues, Bhal, Eshwen, Blekman, Freya, Brau, Benjamin P, Buschmann, Malte, Buttinger, William, Chen, Chunhui, Cheng, Hsin-Chia, Cheong, Sanha, Citron, Matthew, Cormier, Félix, Dall'Occo, Elena, Cosa, Annapaola de, Simone, Andrea De, Rose, Luigi Delle, Deppisch, Frank F, Dey, Biplab, Diamond, Miriam D, Dienes, Keith R, Döbrich, Babette, ElSawy, M, Valle, Alberto Escalante del, Feng, Jonathan L, Fischer, Oliver, Flaecher, H U, Foldenauer, Patrick, Galon, Iftah, Gershtein, Yuri, Giagu, Stefano, Grancagnolo, Sergio, Hajer, Jan, Hammad, Ahmed, Heinrich, Lukas, Heisig, Jan, Hesketh, Gavin, Hill, Christopher S, Hirsch, Martin, Hohlmann, M, Hulsbergen, W, Huth, John, Ilten, Philip, Jacques, Thomas, Kaji, Toshiaki, Kasieczka, Gregor, Kazana, Malgorzata, Keller, Henning, Kolberg, Ted R, Kvam, Audrey, Landsberg, Greg, Lanfranchi, Gaia, Lara, Iñaki, Linthorne, Dylan, Lowette, Steven, Lubatti, Henry, Lutz, Margaret, Mamuz̆i, Judita, McDermott, Kevin, Moortgat, Filip, Morandini, Alessandro, Morris, Alice Polyxeni, Morse, David Michael, Nemevs̆ek, Miha, Pascoli, Silvia, Peña, Cristián, Piedra, Jónatan, Pinfold, James L, Policicchio, Antonio, Prisciandaro, Jessica, Rauco, Giorgia, Roepe, Amber, Ronzani, Manfredi, Sawada, Ryu, Sebastiani, Cristiano, Soffi, Livia, Stolarski, Daniel, Templ, Sebastian, Torró-Pastor, Emma, Trojanowski, Sebastian, Tsai, Yuhsin, Vámi, Tamás Álmos, Vermassen, Basile, Watts, Gordon, Yexley, Melissa, Young, Charles, Yu, Jiang-Hao, Zalewski, Piotr

Volltext

Treatment with hypoxia‐mimetics protects cultured rat Schwann cells against oxidative stress‐induced cell death von David, Brian T., Curtin, Jessica J., Brown, Jennifer L., Coutts, David J. C., Boles, Nathan C., Hill, Caitlin E.

Volltext